Par Drugs & Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 14, 2025, 9:48 pm

Competitors of Par Drugs & Chemicals Ltd

All Competitor Stocks of Par Drugs & Chemicals Ltd

Quarterly Result

Last Updated: August 20, 2025, 5:45 am

Below is a detailed analysis of the quarterly data for Par Drugs & Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 26.05 Cr.. The value appears strong and on an upward trend. It has increased from 22.33 Cr. (Mar 2025) to 26.05 Cr., marking an increase of 3.72 Cr..
• For Expenses, as of Jun 2025, the value is 22.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.90 Cr. (Mar 2025) to 22.49 Cr., marking an increase of 2.59 Cr..
• For Operating Profit, as of Jun 2025, the value is 3.56 Cr.. The value appears strong and on an upward trend. It has increased from 2.43 Cr. (Mar 2025) to 3.56 Cr., marking an increase of 1.13 Cr..
• For OPM %, as of Jun 2025, the value is 13.67%. The value appears strong and on an upward trend. It has increased from 10.88% (Mar 2025) to 13.67%, marking an increase of 2.79%.
• For Other Income, as of Jun 2025, the value is 1.84 Cr.. The value appears strong and on an upward trend. It has increased from 0.79 Cr. (Mar 2025) to 1.84 Cr., marking an increase of 1.05 Cr..
• For Interest, as of Jun 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.02 Cr..
• For Depreciation, as of Jun 2025, the value is 0.90 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.92 Cr. (Mar 2025) to 0.90 Cr., marking a decrease of 0.02 Cr..
• For Profit before tax, as of Jun 2025, the value is 4.48 Cr.. The value appears strong and on an upward trend. It has increased from 2.28 Cr. (Mar 2025) to 4.48 Cr., marking an increase of 2.20 Cr..
• For Tax %, as of Jun 2025, the value is 25.67%. The value appears to be improving (decreasing) as expected. It has decreased from 27.63% (Mar 2025) to 25.67%, marking a decrease of 1.96%.
• For Net Profit, as of Jun 2025, the value is 3.33 Cr.. The value appears strong and on an upward trend. It has increased from 1.65 Cr. (Mar 2025) to 3.33 Cr., marking an increase of 1.68 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.71. The value appears strong and on an upward trend. It has increased from 1.34 (Mar 2025) to 2.71, marking an increase of 1.37.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:43 am

Growth

Last Updated: September 5, 2025, 12:05 pm

Balance Sheet

Last Updated: May 13, 2025, 2:57 pm

Below is a detailed analysis of the balance sheet data for Par Drugs & Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 12.00 Cr..
• For Reserves, as of Mar 2025, the value is 87.00 Cr.. The value appears strong and on an upward trend. It has increased from 73.00 Cr. (Mar 2024) to 87.00 Cr., marking an increase of 14.00 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Mar 2024) to 20.00 Cr., marking an increase of 4.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 119.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 102.00 Cr. (Mar 2024) to 119.00 Cr., marking an increase of 17.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 39.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2024) to 39.00 Cr., marking a decrease of 2.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 25.00 Cr., marking an increase of 25.00 Cr..
• For Other Assets, as of Mar 2025, the value is 55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2024) to 55.00 Cr., marking a decrease of 5.00 Cr..
• For Total Assets, as of Mar 2025, the value is 119.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to 119.00 Cr., marking an increase of 17.00 Cr..

Notably, the Reserves (87.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Par Drugs & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
• For Diluted EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
• For Cash EPS (Rs.), as of Mar 25, the value is 13.82. This value is within the healthy range. It has decreased from 14.58 (Mar 24) to 13.82, marking a decrease of 0.76.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
• For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.06. It has increased from 77.73 (Mar 24) to 82.06, marking an increase of 4.33.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 17.60. This value is within the healthy range. It has decreased from 18.74 (Mar 24) to 17.60, marking a decrease of 1.14.
• For PBIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.95 (Mar 24) to 14.63, marking a decrease of 1.32.
• For PBT / Share (Rs.), as of Mar 25, the value is 14.57. This value is within the healthy range. It has decreased from 15.86 (Mar 24) to 14.57, marking a decrease of 1.29.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.79 (Mar 24) to 10.86, marking a decrease of 0.93.
• For PBDIT Margin (%), as of Mar 25, the value is 21.44. This value is within the healthy range. It has decreased from 24.11 (Mar 24) to 21.44, marking a decrease of 2.67.
• For PBIT Margin (%), as of Mar 25, the value is 17.83. This value is within the healthy range. It has decreased from 20.51 (Mar 24) to 17.83, marking a decrease of 2.68.
• For PBT Margin (%), as of Mar 25, the value is 17.75. This value is within the healthy range. It has decreased from 20.40 (Mar 24) to 17.75, marking a decrease of 2.65.
• For Net Profit Margin (%), as of Mar 25, the value is 13.22. This value exceeds the healthy maximum of 10. It has decreased from 15.16 (Mar 24) to 13.22, marking a decrease of 1.94.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.49. This value is below the healthy minimum of 15. It has decreased from 16.93 (Mar 24) to 13.49, marking a decrease of 3.44.
• For Return on Capital Employeed (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 22.00 (Mar 24) to 17.51, marking a decrease of 4.49.
• For Return On Assets (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 14.27 (Mar 24) to 11.18, marking a decrease of 3.09.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.91. It has decreased from 1.00 (Mar 24) to 0.91, marking a decrease of 0.09.
• For Current Ratio (X), as of Mar 25, the value is 3.31. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 3.31, marking a decrease of 1.48.
• For Quick Ratio (X), as of Mar 25, the value is 2.94. This value exceeds the healthy maximum of 2. It has decreased from 4.46 (Mar 24) to 2.94, marking a decrease of 1.52.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.66. This value is within the healthy range. It has increased from 6.97 (Mar 24) to 7.66, marking an increase of 0.69.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 263.72. This value is within the healthy range. It has increased from 215.31 (Mar 24) to 263.72, marking an increase of 48.41.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.70. This value is within the healthy range. It has increased from 136.40 (Mar 24) to 163.70, marking an increase of 27.30.
• For Enterprise Value (Cr.), as of Mar 25, the value is 76.93. It has decreased from 228.45 (Mar 24) to 76.93, marking a decrease of 151.52.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 2.39 (Mar 24) to 0.76, marking a decrease of 1.63.
• For EV / EBITDA (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 5. It has decreased from 9.91 (Mar 24) to 3.55, marking a decrease of 6.36.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 1.06, marking a decrease of 2.04.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
• For EarningsYield, as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 0.12, marking an increase of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness